Clinical application of the CpG island methylator phenotype to prognostic diagnosis in neuroblastomas

Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas

(2012) Nimrod B Kiss et al.   BMC Medical Genetics

Epigenetic Resensitization to Platinum in Ovarian Cancer

(2012) D. Matei et al.   CANCER RESEARCH

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

A pyrosequencing assay for the quantitative methylation analysis of the PCDHB gene cluster, the major factor in neuroblastoma methylator phenotype

(2011) Barbara Banelli et al.   LABORATORY INVESTIGATION

The Epigenetic promise for prostate cancer diagnosis

(2011) Leander Van Neste et al.   PROSTATE

Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer

(2011) R. A. Juergens et al.   Cancer Discovery

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease

(2010) Elena Grau et al.   MOLECULAR CARCINOGENESIS

Recent Advances in Neuroblastoma

(2010) John M. Maris   NEW ENGLAND JOURNAL OF MEDICINE

Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group study

(2010) Rani E. George et al.   PEDIATRIC BLOOD & CANCER

Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors

(2010) Lisa A Cowan et al.   Epigenomics

Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy

(2009) J. H. Schulte et al.   CANCER RESEARCH

IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype

(2009) Hiromu Suzuki et al.   CARCINOGENESIS

Three DNA Methylation Epigenotypes in Human Colorectal Cancer

(2009) K. Yagi et al.   CLINICAL CANCER RESEARCH

Identification of Cell-Active Lysine Specific Demethylase 1-Selective Inhibitors

(2009) Rie Ueda et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

Analysis of the Association between CIMP and BRAFV600E in Colorectal Cancer by DNA Methylation Profiling

(2009) Toshinori Hinoue et al.   PLoS One

CpG island methylator phenotype (CIMP) in cancer: Causes and implications

(2008) Jens M. Teodoridis et al.   CANCER LETTERS

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

(2008) S. Ogino et al.   GUT

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

(2008) Susan L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of Genes Targeted by CpG Island Methylator Phenotype in Neuroblastomas, and Their Possible Integrative Involvement in Poor Prognosis

(2008) Masanobu Abe et al.   ONCOLOGY